Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $133.69 million. The enterprise value is -$19.03 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 38.58 million shares outstanding. The number of shares has increased by 145.71% in one year.
| Current Share Class | 38.58M |
| Shares Outstanding | 38.58M |
| Shares Change (YoY) | +145.71% |
| Shares Change (QoQ) | +54.01% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 71.72% |
| Float | 34.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.03, with a Debt / Equity ratio of 0.03.
| Current Ratio | 18.03 |
| Quick Ratio | 17.77 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.88% and return on invested capital (ROIC) is -28.40%.
| Return on Equity (ROE) | -41.88% |
| Return on Assets (ROA) | -27.16% |
| Return on Invested Capital (ROIC) | -28.40% |
| Return on Capital Employed (ROCE) | -31.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.38M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.14% in the last 52 weeks. The beta is 1.72, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.72 |
| 52-Week Price Change | +12.14% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 3.42 |
| Relative Strength Index (RSI) | 47.77 |
| Average Volume (20 Days) | 479,939 |
Short Selling Information
The latest short interest is 2.48 million, so 6.42% of the outstanding shares have been sold short.
| Short Interest | 2.48M |
| Short Previous Month | 2.03M |
| Short % of Shares Out | 6.42% |
| Short % of Float | 7.24% |
| Short Ratio (days to cover) | 4.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.43M |
| Pretax Income | -40.69M |
| Net Income | -45.42M |
| EBITDA | -51.10M |
| EBIT | -51.43M |
| Earnings Per Share (EPS) | -$1.63 |
Full Income StatementBalance Sheet
The company has $124.36 million in cash and $4.23 million in debt, giving a net cash position of $153.29 million or $3.97 per share.
| Cash & Cash Equivalents | 124.36M |
| Total Debt | 4.23M |
| Net Cash | 153.29M |
| Net Cash Per Share | $3.97 |
| Equity (Book Value) | 158.48M |
| Book Value Per Share | 4.11 |
| Working Capital | 119.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$40.14 million and capital expenditures -$107,000, giving a free cash flow of -$40.25 million.
| Operating Cash Flow | -40.14M |
| Capital Expenditures | -107,000 |
| Free Cash Flow | -40.25M |
| FCF Per Share | -$1.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |